Eurand Says Two Dose Regimen Of Zenpep Improve Fat...
(RTTNews) - Pharmaceutical company Eurand N.V. (EURX: News ), said Friday that data from its trial using Zenpep delayed release capsule in two dose regimen showed an... More »
RTTNews.com - Nov. 13, 2009
Phase II/III Clinical Study Compares Safety and Efficacy of...
Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study demonstrating that ZENPEP(TM) (pancrelipase)... More »
Genetic Engineering News - Nov. 13, 2009
Phase II/III Clinical Study Compares Safety and Efficacy of...
... porcine-derived pancreatic enzyme products may increase blood uric acid levels. Caution should be exercised for patients with known allergies to proteins of porcine... More »
Earthtimes.org - Nov. 13, 2009
Phase II/III Clinical Study Compares Safety and Efficacy of...
PHILADELPHIA, PA -- (Marketwire) -- 11/13/09 -- Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study... More »
PR inside - Nov. 13, 2009
Phase II/III Clinical Study Compares Safety and Efficacy of...
Eurand N.V. (NASDAQ: EURX), a global specialty pharmaceutical company, today announced data from a Phase II/III clinical study demonstrating that ZENPEP(TM) (pancrelipase)... More »
Market Wire via MSN Money - Nov. 13, 2009
Eurand Says Data Shows ZENPEP Delayed-Release Capsules...
(RTTNews) - Eurand N.V. (EURX: News ) announced data from a Phase II/III clinical study demonstrating that ZENPEP Delayed-Release Capsules significantly improves fat... More »
RTTNews.com - Nov. 13, 2009
Market Report -- In Play (EURX)
Eurand announces data from a Phase II/III clinical study demonstrating that ZENPEP delayed-release capsules significantly improves fat absorption in patients with exocrine... More »
Briefing.com via MSN Money - Nov. 13, 2009